Clinical Discovery Research Reagents

Are you ready to be part of something special?



Advancing clinical discovery research

With our Clinical Discovery Research Reagents (CDRR) we want to help clinical researchers advance their clinical discovery. Our recently expanded portfolio of antibodies and bright fluorescent dyes enables BD to offer a broad selection of kits to advance your clinical research needs.

Placeholder


Two new kits offering you improved stability

BD Horizon™ Dri Leukocytes

Placeholder

Convenience


Ready-to-use and provides greater accessibility and convenience as compared to fresh blood, with >150 markers. It also maintains resolution of rare populations, including expression of basophils and dendritic cells

Placeholder

Stability


One-year shelf life at 2-8°C

BD Horizon™ Dri TBNK+CD20

Placeholder

Reduced variability


The kits can be used across labs and sites to help improve research consistency

Placeholder

Stability


With the introduction of our dry panel offerings, you receive improved shelf life over liquid cocktails and storage at room temperature






BD Horizon™ Dri Leukocytes


BD Horizon™ Dri Leukocytes are dried lysed whole blood control cells that can be used as positive, negative and procedural controls in a variety of flow cytometric applications.

   MORE PRODUCTS DETAILS



Product Details

Cell count: 2 x 106 to 3 x 106 cells per tube
Stability: 12 months from manufacturing date, 5 days after reconstitution
Package: The kit includes 1 pouch of 5 tubes and 1 vial of reconstitution buffer.


Supporting Data

Placeholder

Figure 1. Scatter profiles of fresh blood vs BD Horizon Dri Leukocytes


Figure 2. Workflow using BD Horizon Dri Leukocytes


Marker Clone Marker Clone Marker Clone Marker Clone
CD1b M-T101 CD42a ALMA.16 CD89 A59 CD196 11A9
CD1d CD1d-41 CD42b HIP1 CD91 A2MR-alpha CD200 MRC
CD2 RPA-2.10 CD43 1G10 CDw93 R139 CD205 MG38
CD3 HIT3a CD44 G44-26 CD94 HP-3D9 CD209 DCN46
CD4 RPA-T4 CD45 HI30 CD95 DX2 CD221 3B7
CD4v4 L120 CD45RA HI100 CD97 VIM3b CD226 DX11
CD5 L17F12 CD45RB MT4 CD98 UM7F8 CD227 HMPV
CD6 M-T605 CD45RO UCHL1 CD99 TU12 CD229 HLy9.1.25
CD7 M-T701 CD46 E4.3 CD99R HIT4 CD243 17F9
CD8a SK1 CD47 B6H12 CD100 A8 CD244 Feb-69
CD8b 2ST8.5H7 CD48 TU145 CD102 CBR-1C2/2.1 CD255 CARL-1
CD9 M-L13 CD49b AK-7 CD105 266 CD268 11C1
CD10 HI10a CD49c C3 CD107a H4A3 CD271 C40-1457
CD11a G43-25B CD49d 9F10 CD107b H4B4 CD275 2D3/B7-H2
CD11b D12 CD49e VC5 CD108 KS-2 CD282 11G7
CD11c B-ly6 CD50 TU41 CD109 TEA CD305 DX26
CD13 WM15 CD53 HI29 CD119 GIR-208 CD314 1D11
CD14 M5E2 CD54 LB-2 CD122 Mik-beta CD321 M.AB.F11
CD15 HI98 CD55 IA10 CD123 9F5 CDw328 F023-420
CD15s CSLEX1 CD56 B159 CD126 M5 CD329 E10-286
CD16 3G8 CD57 NK-1 CD127 hIL-7R-M21 CD335 9E2/NKp-46
CD18 6.7 CD58 1C3 CD128b 6C6 CD337 P30-15
CD19 HIB19 CD59 p282 CD130 AM64 αβTCR T10B9.1A-31
CD20 2H7 CD61 VI-PL2 CD140a alpha β2-microglobulin TU99
CD21 B-ly4 CD62E 68-5H11 CD140b 28D4 BLTR-1 203/14F11
CD23 EBVCS-5 CD62L Dreg CD141 1A4 Fmlp-R 5F1
CD24 ML5 CD62P AK-4 CD147 HIM6 HLA-A,B,C G46-2.6
CD25 M-A251 CD63 H5C6 CD151 14A2.H1 HLA-A2 BB7.2
CD26 M-A261 CD64 10.1 CD152 BNI3 HLA-DQ TU169
CD27 M-T271 CD66 (acde) CD158b CH-L HLA-DR G46-6 (L243)
CD28 L293 CD66b G10F5 CD161 DX12 HLA-DR, DP, DQ TU39
CD29 HUTS-21 CD70 Ki-24 CD162 KPL-1 Disialoganglioside
GD2
14.G2a
CD30 BerH8 CD71 M-A712 CD163 GHI/61 MIC A/B 6D4
CD31 WM59 CD72 J4-117 CD164 N6B6 SSEA-1 MC480
CD32 FL18.26 CD73 AD2 CD165 SN2 CD326 EBA-1
CD33 HIM3-4 CD74 M-B741 CD166 3A6 Ms IgG2a IC G155-178
CD35 E11 CD79b CB3-1 CD171 5G3 CD49f GoH3
CD36 CB38 CD80 L307.4 CD172b B4B6 CD104 439-9B
CD37 M-B371 CD81 JS-81 CD177 MEM-166 CD120b hTNFR-M1
CD38 HIT2 CD84 2G7 CD180 G28-8 CD132 TUGh-4
CD39 TU66 CD85 GHI/75 CD181 5A12 CD210 3F9
CD40 5C3 CD86 2331 CD183 1c6/cxcr3 CLA HECA-452
CD41A HIP8 CD87 VIM5 CD184 12G5 Integrin β7 FIB504
CD41b HIP2 CD88 D53-1473 CD195 2D7/CCR5 Rt IgG2b IC A95-1

Table 1.175+ Surface Markers Expressed on BD Horizon Dri Leukocytes 175+ surface markers were expressed on BD Horizon Dri Leukocytes. BD Horizon Dri Leukocytes were stained with 240 human cell surface markers using BD Lyoplate™ screening panels (Cat. No. 560747). The screening was carried out with the automated BD™ High Throughput Sampler on the BD FACSCanto™ system or the BD FACS™ Universal Loader on BD FACSLyric™ systems using the manufacturer’s suggested screening protocol. The data was analyzed using BD FACSDiva™, BD FACSuite™ or FlowJo® software. The analysis suggest that more than 175 surface markers are consistently expressed on BD Horizon Dri Leukocytes. And the list of markers is expanding as more markers are screened across multiple lots of BD Horizon Dri Leukocytes.

Storage

BD Horizon Dri Leukocytes should be at stored at 2°C to 8°C. They should not be frozen. Protect the tubes from exposure to humidity during storage and protect from light during and after staining. The cells and reconstitution buffer are stable until the expiration date shown on the labels when stored as directed. Do not use after the expiration date. Due to the moisture sensitivity of BD Horizon Dri Leukocytes, ensure the pouch is immediately and completely resealed after removing a tube. Do not remove the desiccant from the pouch.

Procedure for direct immunostaining of surface markers

  1. Equilibrate the pouch to room temperature for 5 minutes before opening.
  2. Remove the desired tubes from pouch and immediately reseal the pouch for long-term storage at 2–8°C.
  3. Add 500 µL of BD Horizon Dri Leukocyte reconstitution buffer to one tube. Vortex gently to mix.
    Note: Each tube contains 5 tests. 100 µL re-suspended cells per test is recommended.
  4. Add the appropriate volume of staining reagent to each tube, vortex and incubate in the dark for 20 to 30 minutes at room temperature.
  5. Add 2 mL of 1X PBS wash buffer to the tube. Vortex to mix.
  6. Centrifuge for 5 minutes at 300–500 g.
  7. Aspirate the supernatant and re-suspend stained cells in 400 µL of 1% paraformaldehyde (PFA).
  8. Acquire immediately or store at 2–8°C and acquire within 24 hours of staining.

Visit our website www.bdbiosciences.com/reagents or contact your local BD representative for a comprehensive list of cellular and intracellular markers tested, or specific staining procedures.

Product notices

This product is made from normal whole human blood cells. The blood used in preparation of this product is tested and found to be negative for human immunodeficiency virus (HIV) type 1 and type 2, and the hepatitis B and hepatitis C viruses. This product contains the preservative ProClin™. All biological specimens are considered biohazards. Handle as if capable of transmitting infection and dispose of with proper precautions in accordance with federal, state and local regulations. Never pipette by mouth. Wear suitable protective clothing, eyewear and gloves.

Resources

Data sheet - BD Horizon™ Dri Leukocyte Control Cells
Dried Controls Cells for Flow Cytometry and Beyond
Studies to Demonstrate the Convenience, Consistency, Stability and Staining Performance of BD Horizon™ Dri Leukocyte Controls



BD Horizon™ Dri TBNK+CD20


BD Horizon™ Dri TBNK+CD20 is a dried reagent panel comprising the same conjugates that are in the BD Multitest™ 6-color TBNK reagent with the addition of CD20 V450. 

   MORE PRODUCTS DETAILS



Product Details

BD Horizon Dri TBNK+CD20 is a dried reagent panel comprising the following conjugates:


Format V450 FITC PE PE PerCP-Cy™5.5 PE-Cy™7 APC APC-Cy7
Specificity CD20 CD3 CD16 CD56 CD45 CD4 CD19 CD8
Clone L27 SK7 B73.1 NCAM16.2 2D1 (HLe-1) SK3 SJ25C1 Sk1

Supporting Data

Figure 1. Flow cytometric analysis results
Flow cytometric analysis was performed on whole blood stained using either the BD Multitest™ 6- color TBNK reagent with a CD20 V450 drop-in (Figure 1A) or BD Horizon Dri TBNK+CD20 tube (Figure 1B). Laser excitation was at 405 nm, 488 nm, or 635 nm.

Figure 2. Absolute count of lymphocytes
Stained samples (using BD Multitest 6-color TBNK reagent with a CD20 V450 drop-in and BD Horizon Dri TBNK+CD20 tubes) prepared using three donors were transferred to BD Trucount™ tubes, acquired using the BD FACSLyric™ or BD FACSCanto™ systems and analyzed for determination of absolute counts of lymphocytes in blood (Figures 2A and 2B).


Optional Compensation Reagents

  • Batch-matched compensation reagent CD4 PE-Cy7
  • Batch-matched compensation reagent CD8 APC-Cy7

Storage

Store tubes in their original foil pouch at 2-27°C. Do not freeze the reagent or expose it to direct light at any time during storage or incubation with cells. Once the pouch is opened, use the remaining tubes within one month (when stored as directed). Do not use reagents beyond the expiration date indicated on the label. CAUTION: Due to the moisture sensitivity of the reagent, ensure the pouch is immediately and completely resealed after removing a tube. Do not remove the desiccant from the reagent pouch.


Preparation

Refer to our website or contact your local BD representative for the lyse/no-wash protocol for direct immunofluorescence. Use aseptic blood collected in EDTA (ethylenediamine-tetraacetic acid) blood collection tubes.

  • Add 50 μl of well-mixed, anticoagulated whole blood in to the bottom of the air-dried reagent cocktail tube and mix to complete reconstitution by gentle pipetting/vortexing for four seconds. Incubate 15 minutes at room temperature. Protect from exposure to direct light.
  • Add 450 μl of 1X BD FACS™ lysing solution to the tube. Vortex to mix. Incubate for 15 minutes in the dark at room temperature.
  • The sample is analyzed on a flow cytometer with a setup optimized for antibody panels.

Resources

Immune Monitoring of Patients Receiving Rituximab Therapy
Data sheet - BD HorizonTM Dri TBNK+CD20



BD support and information


To support you, we have prepared support protocols and posters. Follow the “More information” button below to access these documents.

   MORE INFORMATION

Yes I would like to know more! Please ask a BD representative to contact me